AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Adagene Reports Promising 2025 Financial Results, Advances Pipeline with FDA Alignment, and Expands Cash Runway with Sanofi Partnership.
ByAinvest
Tuesday, Aug 12, 2025 4:07 pm ET1min read
Adagene reported 6-month 2025 financial results and provided corporate updates. The company's Phase 1b/2 trial for Muzastotug (ADG126) in MSS CRC showed a 19.4-month median OS in the 10 mg/kg dose cohorts. The FDA has been aligned on Phase 2 and Phase 3 trial design elements, and the company expects to begin enrolling patients in Phase 2 in 2H 2025. A strategic investment of up to $25 million from Sanofi has extended Adagene's cash runway into 2027.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet